Showing results for Policy News

July 10, 2019

Today, organizations representing patients, providers, medical researchers, survivors, and their families joined together to call on Congress to improve access to clinical trials for patients with life-threatening diseases. The coalition, which is made up of 86 supporting organizations, is urging Congress to pass the bipartisan CLINICAL TREATMENT Act (H.R. 913), which would guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition.

May 29, 2019

The American Society of Clinical Oncology (ASCO) today announced the Health Policy Leadership Development Program Fellows for the 2019-2020 class. Wendy Allen-Rhoades, MD, of Baylor College of Medicine, and Laura LaNiel Tenner, MD, MPH, of The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, will spend the next year developing leadership skills and healthcare policy expertise. During their fellowship, Dr. Allen-Rhoades and Dr. Tenner will participate in ASCO efforts to shape cancer-related policies that directly affect individuals with cancer and the oncology practice environment.

May 17, 2019

The American Society of Clinical Oncology (ASCO) applauds the Centers for Medicare & Medicaid Services (CMS) for listening to ASCO and other stakeholders by not finalizing a proposal that would have significantly impacted access to drugs within the Six Protected Classes.

May 7, 2019

Today, the American Society of Clinical Oncology (ASCO) and the American Cancer Society Cancer Action Network (ACS CAN) will host a joint reception on Capitol Hill for Members of Congress to underscore the two organizations’ shared policy priorities to improve research and cancer care delivery for patients and cancer survivors.

April 9, 2019

The American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the National Comprehensive Cancer Network® (NCCN) are pleased to acknowledge receipt of a key clarification from the Centers for Disease Control and Prevention (CDC) on prescribing opioids to manage pain from certain conditions. The clarification regarding CDC’s Guideline for Prescribing Opioids for Chronic Pain—issued in a letter from the agency to ASCO, ASH, and NCCN—comes as a result of a collaborative effort by these organizations to clarify CDC’s opioid prescribing guideline in order to ensure safe and appropriate access for cancer patients, cancer survivors, and individuals with sickle cell disease.

April 2, 2019

The results of a recently released survey conducted for the American Cancer Society Cancer Action Network (ACS CAN) raise serious concerns about the negative impact that utilization management practices, including prior authorization requirements, are having on patients with cancer and their physicians. The survey results reinforce ASCO’s position that payer-imposed utilization management strategies must provide people with cancer full access to the right treatment, at the right time, based on the scientific evidence on what constitutes high-quality care.

March 12, 2019

"We strongly oppose the White House budget proposal for Fiscal Year (FY) 2020, which would stall our nation’s progress against cancer and impede access to needed care for the millions of Americans dealing with cancer. The proposal would make drastic, unprecedented cuts to the U.S. Department of Health and Human Services—which houses the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Medicare & Medicaid Services (CMS)."

January 11, 2019

ASCO congratulates Anand Shah, MD, MPH, on being named Senior Medical Advisor for Innovation at the Centers for Medicare & Medicaid Services (CMS). In his new role, Dr. Shah will lead efforts across CMS to advance medical innovation reporting directly to CMS Administrator Seema Verma.

.

January 8, 2019

The American Society of Clinical Oncology (ASCO) today published standards on the safe handling of hazardous drugs in the Journal of Clinical Oncology. ASCO’s standards largely endorse best practices issued by other stakeholder groups for safely handling hazardous drugs but offer alternatives in several key areas where more research is needed to identify evidence-based safety measures.